Those of us in the inhibitor community who attended the Inhibitor Summits have been hearing about future therapies that would potentially provide more efficacious treatment for years. As with all product development, the process to get to market is long, and not always successful. Product safety remains a priority, especially for our bleeding disorder community. These new therapies, however, bring hope to the inhibitor community; especially for those with hemophilia B and an inhibitor who have very few options for effective treatment. Rebalancing therapies that increase thrombin by lowering anticoagulants are within reach. There is a lot to know and understand about their mechanism of action.
Familiarize yourself with the vocabulary
Take advantage of webinars or educational resources as they present themselves
And ask your healthcare professional (HCP) LOTS of questions
Product choice is ultimately a decision made between you/your child and your HCP. We know well in this community, that not every product works the same for everyone, and if you know one inhibitor patient-you know ONE inhibitor patient.
